ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe. Mr. Comiskey has a successful track record in the planning, organization and execution of product launches. Over the course of his career, he has demonstrated innovative, solutio
Outlook Therapeutics, Inc. announced the appointment of Jedd Comiskey as Senior VP ? Head of Europe. Mr. Comiskey has a successful track record in the planning, organization and execution of product.